Biochip Development: Strategic Alignment to Global Best Practices
Good afternoon,
As we ramp up activities related to the development of Archer’s biochip, I wanted to provide shareholders with two important resources that help in providing some context to how the Company’s activity aligns nationally and globally.
Firstly,a publicationfrom the Bulletin of the World Health Organization, titled “A guide to aid the selection of diagnostic tests”.
In the publication: - A six-step approach to overcoming the obstacles in selecting and implementing in vitro diagnostic tests is reported. This approach was derived from a review of the diagnostics literature, and from reputable organisations’ experience with implementing diagnostics programmes.
- The challenges involved in each of the six steps are discussed, while also providing an outline of current problems with the quality assurance of tests.
This publication is a guide to the global challenges that exist in the development of diagnostic testing, and highlights areas of greatest importance and value-add to key end-use stakeholders.
Secondly, the Australian Government’s Medical Products National Manufacturing PriorityRoad Map.
The Road Map:- Recognises Australian medical products have the potential for global capability and capacity. The focus is on local manufacturing of advanced and high-value products using sophisticated processes.
- Key growth opportunities include medical devices, including diagnostics, and data-driven digitally integrated products and platforms; these areas apply to Archer’s biochip development.
The Road Map provides an insight into areas of national strategic priority and describes opportunities for high-value growth over the next 2-5 years in medical product manufacturing and commercialisation in Australia.
Sincerely,
Dr Mohammad Choucair, FRACI FRSN GAICD
Chief Executive Officer
Archer Materials Limited (ASX:AXE)
| 
(20min delay)